{"protocolSection":{"identificationModule":{"nctId":"NCT06478381","orgStudyIdInfo":{"id":"HNSZLYYML09"},"organization":{"fullName":"Henan Cancer Hospital","class":"OTHER_GOV"},"briefTitle":"L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma","officialTitle":"A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of L218CAR19 in Patients With CD19 Positive Relapsed/Refractory B-cell Lymphomas"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-06-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-16","studyFirstSubmitQcDate":"2024-06-22","studyFirstPostDateStruct":{"date":"2024-06-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-22","lastUpdatePostDateStruct":{"date":"2024-06-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Yanyan Liu","investigatorTitle":"Professor","investigatorAffiliation":"Henan Cancer Hospital"},"leadSponsor":{"name":"Henan Cancer Hospital","class":"OTHER_GOV"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"L218CAR19 is a kind of chimeric antigen receptor T-cell immunotherapy targeting CD19 on B cells. The goal of this study is to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of L218CAR19 in patients with B-cell lymphomas who have received at least two lines of systemic treatment."},"conditionsModule":{"conditions":["Relapsed/Refractory B-cell Lymphomas"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":22,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Dose Escalation","type":"EXPERIMENTAL","description":"L218CAR19 is administered via infusion with ascending dose levels to determine the maximum tolerated dose (MTD)","interventionNames":["Drug: L218CAR19"]}],"interventions":[{"type":"DRUG","name":"L218CAR19","description":"L218CAR19 is intravenously administered at three dose levels.","armGroupLabels":["Dose Escalation"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Dose limiting toxicity (DLT)","description":"Occurrence of DLTs","timeFrame":"Up to 4 weeks"},{"measure":"Treatment-emergent adverse event (AE)","description":"Incidence of treatment-emergent AEs","timeFrame":"Up to 1 year"}],"secondaryOutcomes":[{"measure":"Quantification of L218CAR19 in peripheral blood","description":"To quantify L218CAR19 in a patient's peripheral blood at different time points","timeFrame":"Up to 1 year"},{"measure":"Time to reach Cmax (Tmax) of L218CAR19","description":"To identify the time point when the concentration of L218CAR19 reaches maximum in a patient's peripheral blood","timeFrame":"Up to 3 months"},{"measure":"Area under the curve (AUC) of L218CAR19","description":"To quantify the cumulative amount of L218CAR19 in a patient's peripheral blood over time","timeFrame":"Up to 3 months"},{"measure":"Clearance (CL) of L218CAR19","description":"To determine the clearance factor of L218CAR19 in a patient's peripheral blood","timeFrame":"Up to 3 months"},{"measure":"Immunogenic response to L218CAR19","description":"To evaluate the anti-drug antibodies in response to L218CAR19 administration in a patient's peripheral blood","timeFrame":"Up to 1 year"},{"measure":"Serum cytokine concentrations","description":"To measure the cytokine levels (e.g. TNFa, IL-6, IL-1, IL-2, etc.) in a patient's peripheral blood at different time points","timeFrame":"Up to 3 months"},{"measure":"ORR","description":"To determine the overall (best) objective anti-cancer response by Lugano criteria","timeFrame":"Up to 1 year"},{"measure":"PFS","description":"To evaluate the duration of patient's progression-free survival","timeFrame":"Up to 1 year"},{"measure":"OS","description":"To evaluate the overall duration of patient's survival","timeFrame":"Up to 1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18-75 years at the time of inclusion\n* Written informed consent\n* Patients with relapsed/refractory CD19 positive B-cell lymphomas, who have received at least two lines of treatment\n* With measurable disease\n* ECOG PS 0-2 at protocol entry\n* Estimated life expectancy of 3 months or longer\n* Hemoglobin ≥ 8 g/dL (≥5 mmol/l); Platelets ≥ 75 x 10E9/L; Absolute neutrophil count ≥ 1.0 x 10E9/L; Platelets ≥ 50 x 10E9/L permitted if documented bone marrow involvement; Serum bilirubin ≤ 1.5 x upper limit of normal (ULN), or ≤3 x ULN if elevation is due to hepatic involvement by lymphoma; Serum glutamic-oxaloacetic transaminase (AST) and/or serum glutamic-pyruvic transaminase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN if elevation is due to hepatic involvement by lymphoma; Serum creatinine ≤ 1.5 x ULNb; left ventricular ejection fraction (LVEF) ≥ 50%\n* Women of childbearing potential must use safe anticonception (e.g. contraceptive pills, intrauterine devices etc.) during the study and 6 months after the administration of study drug; Male patients must use contraception for the duration of the study and 6 months after the administration of study drug if his partner is of childbearing potential\n\nExclusion Criteria:\n\n* Patients with heart disease: atrial fibrillation; History of Class III or IV New York Heart Association (NYHA) heart failure, myocardial infarction or other significant cardiac disease within 12 months of screening; LVEF\\<50%; clinical significant pericardial effusion; Long QT syndrome\n* History of severe pulmonary function impairment\n* With other uncontrolled malignancy\n* With active bacterial, viral, or fungal infections\n* WIth uncontrolled autoimmune disease or congential immunodeficiency\n* HIV antibody positive patients\n* Known severe hypersensitivity to biological product\n* Patients with known active central nervous system (CNS) disease, including lymphoma CNS involvement\n* Patients with prior CAR-T therapy\n* History of allogeneic stem cell transplantation\n* History of autogeneic stem cell transplantation within 6 months of screening\n* History of major surgery within 4 weeks of screening\n* Patients receiving live (attenuated) vaccines within 6 weeks of screening\n* Pregnant or lactating women, or pregnant plan within 12 months\n* Involvement of cardiac tissue by lymphoma\n* with emergency due to oncothlipsis\n* Unwillingness or inability to comply with the protocol\n* Deemed 'unfit' by the treating physician","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Yanyan Liu","role":"CONTACT","phone":"86 037165587791","email":"yyliu@zzu.edu.cn"},{"name":"Zheng Yan","role":"CONTACT","phone":"86 13598097015","email":"zlyyyanzheng3920@zzu.edu.cn"}],"overallOfficials":[{"name":"Yanyan Liu","affiliation":"Affiliated Cancer Hospital of Zhengzhou University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Affiliated Cancer Hospital of Zhengzhou University","status":"RECRUITING","city":"Zhengzhou","state":"Henan","zip":"450008","country":"China","contacts":[{"name":"Yanyan Liu","role":"CONTACT","phone":"86-037165587791","email":"yyliu@zzu.edu.cn"},{"name":"Zheng Yan","role":"CONTACT","phone":"86+13598097015","email":"zlyyyanzheng3920@zzu.edu.cn"}],"geoPoint":{"lat":34.75778,"lon":113.64861}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000008223","term":"Lymphoma"},{"id":"D000016393","term":"Lymphoma, B-Cell"}],"ancestors":[{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000008232","term":"Lymphoproliferative Disorders"},{"id":"D000008206","term":"Lymphatic Diseases"},{"id":"D000007160","term":"Immunoproliferative Disorders"},{"id":"D000007154","term":"Immune System Diseases"},{"id":"D000008228","term":"Lymphoma, Non-Hodgkin"}],"browseLeaves":[{"id":"M11220","name":"Lymphoma","asFound":"Lymphoma","relevance":"HIGH"},{"id":"M18828","name":"Lymphoma, B-Cell","asFound":"B-cell Lymphoma","relevance":"HIGH"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M11225","name":"Lymphoproliferative Disorders","relevance":"LOW"},{"id":"M11203","name":"Lymphatic Diseases","relevance":"LOW"},{"id":"M10206","name":"Immunoproliferative Disorders","relevance":"LOW"},{"id":"M10200","name":"Immune System Diseases","relevance":"LOW"},{"id":"M11222","name":"Lymphoma, Non-Hodgkin","relevance":"LOW"},{"id":"T3543","name":"Lymphosarcoma","asFound":"Lymphoma","relevance":"HIGH"},{"id":"T640","name":"B-cell Lymphoma","asFound":"B-cell Lymphoma","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"BC20","name":"Immune System Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}